Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001214659-26-002024·Spyre Therapeutics, Inc.
Schedule 13G ownership disclosure
Spyre Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 00773J202
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLC
Shares: 1,892,200.00 · Class: 2.4%
- KEVIN TANG
Shares: 1,892,200.00 · Class: 2.4%
- TANG CAPITAL PARTNERS, LP
Shares: 1,012,338.00 · Class: 1.3%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 879,862.00 · Class: 1.1%
- TANG CAPITAL PARTNERS III, INC
Shares: 0.00 · Class: 0.0%
- TANG CAPITAL PARTNERS IV, INC
Shares: 0.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-26-002024
- Form type
- SCHEDULE 13G/A
- Filer
- Spyre Therapeutics, Inc.
- CIK
- CIK 1636282
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership